Christopher Liu
Stock Analyst at Leerink Partners
(2.50)
# 2,300
Out of 4,893 analysts
5
Total ratings
50%
Success rate
24.55%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Liu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLAY Relay Therapeutics | Maintains: Outperform | $19 → $18 | $3.60 | +400.00% | 1 | Dec 4, 2024 | |
| IDYA IDEAYA Biosciences | Downgrades: Market Perform | $41 → $27 | $22.63 | +19.31% | 2 | Nov 5, 2024 | |
| NUVL Nuvalent | Initiates: Market Perform | $42 | $81.74 | -48.62% | 1 | Aug 8, 2023 | |
| EXEL Exelixis | Initiates: Market Perform | $18 | $45.39 | -60.34% | 1 | Aug 8, 2023 |
Relay Therapeutics
Dec 4, 2024
Maintains: Outperform
Price Target: $19 → $18
Current: $3.60
Upside: +400.00%
IDEAYA Biosciences
Nov 5, 2024
Downgrades: Market Perform
Price Target: $41 → $27
Current: $22.63
Upside: +19.31%
Nuvalent
Aug 8, 2023
Initiates: Market Perform
Price Target: $42
Current: $81.74
Upside: -48.62%
Exelixis
Aug 8, 2023
Initiates: Market Perform
Price Target: $18
Current: $45.39
Upside: -60.34%